UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 47

Sortiert nach

BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8 + cytotoxic T lymphocytes against multiple myeloma: clinical applications

Leukemia, 2020-01, Vol.34 (1), p.210-223

2020

Volltextzugriff (PDF)

Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways

Leukemia, 2021-01, Vol.35 (1), p.177-188

2021

Volltextzugriff (PDF)

Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma

Leukemia, 2022-01, Vol.36 (1), p.138-154

2022

Volltextzugriff (PDF)

Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8 + cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy

Leukemia, 2019-09, Vol.33 (9), p.2208-2226

2019

Volltextzugriff (PDF)

Correction: BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8 + cytotoxic T lymphocytes against multiple myeloma: clinical applications

Leukemia, 2020-07, Vol.34 (7), p.1971-1971

2020

Volltextzugriff (PDF)

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

Cancer research (Chicago, Ill.), 2005-12, Vol.65 (24), p.11712-11720

2005

Volltextzugriff (PDF)

Immunotherapy Strategies in Multiple Myeloma

Hematology/oncology clinics of North America, 2014-10, Vol.28 (5), p.927-943

2014

Volltextzugriff (PDF)

Phenotypic and Functional Effects of Heat Shock Protein 90 Inhibition on Dendritic Cell

Journal of Immunology, 2007-06, Vol.178 (12), p.7730-7737

2007

Volltextzugriff (PDF)

O13-5 Rejuvenated BCMA-specific CD8αβ+ memory T cells to treat multiple myeloma using induced pluripotent stem cell technology

Annals of oncology, 2023-11, Vol.34, p.S1389-S1390

2023

Volltextzugriff (PDF)

Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors

Leukemia, 2018-09, Vol.32 (9), p.1932-1947

2018

Volltextzugriff (PDF)

Development of B-cell maturation antigen (BCMA)-specific CD8 + cytotoxic T lymphocytes using induced pluripotent stem cell technology for multiple myeloma

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.2542-2542

2022

Volltextzugriff (PDF)

Correction: BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8.sup.+ cytotoxic T lymphocytes against multiple myeloma: clinical applications

Leukemia, 2020-07, Vol.34 (7), p.1971

2020

Volltextzugriff (PDF)

BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8.sup.+ cytotoxic T lymphocytes against multiple myeloma: clinical applications

Leukemia, 2020-01, Vol.34 (1), p.210

2020

Volltextzugriff (PDF)

Enhanced CD138 peptide-specific cytotoxic T lymphocyte activities against breast, colon and pancreatic cancers in combination with pembrolizumab (anti-PD1)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14302-e14302

2019

Volltextzugriff (PDF)

Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8.sup.+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy

Leukemia, 2019-09, Vol.33 (9), p.2208

2019

Volltextzugriff (PDF)

Identification of CD19 and CD20 Peptides for Induction of Antigen-Specific CTLs against B-Cell Malignancies

Clinical cancer research, 2005-02, Vol.11 (4), p.1629-1638

2005

Volltextzugriff (PDF)

Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial

JAMA oncology, 2018-12, Vol.4 (12), p.e183267

2018

Volltextzugriff (PDF)

Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells

The Journal of immunology (1950), 2013-02, Vol.190 (3), p.1360-1371

2013

Volltextzugriff (PDF)

OP01-5 Combination immunotherapy targeting XBP1, CD138 and CS1 with cancer vaccine, checkpoint inhibitors, immune modulator, and epigenetic regulator to treat patients with myeloma or solid tumours: Clinical applications

ESMO open, 2023-12, Vol.8 (1), p.102126, Article 102126

2023

Volltextzugriff (PDF)

Myeloma-Specific Multiple Peptides Able to Generate Cytotoxic T Lymphocytes: A Potential Therapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders

Clinical cancer research, 2012-09, Vol.18 (17), p.4850-4860

2012

Volltextzugriff (PDF)

Heteroclitic CD33 Peptide With Enhanced Anti-Acute Myeloid Leukemic Immunogenicity

Clinical cancer research, 2004-10, Vol.10 (20), p.7043-7052

2004

Volltextzugriff (PDF)

A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients

Leukemia, 2015-01, Vol.29 (1), p.218-229

2015

Volltextzugriff (PDF)

P-083: Rejuvenated BCMA-specific CD8+ Cytotoxic T lymphocytes derived from induced pluripotent stem cells for treatment of Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2021-10, Vol.21, p.S84-S84

2021

Volltextzugriff (PDF)

Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma

Leukemia, 2018-03, Vol.32 (3), p.752-764

2018

Volltextzugriff (PDF)

1220 Development of B cell maturation antigen (BCMA)-specific CD8+ cytotoxic T lymphocytes using induced pluripotent stem cell technology for multiple myeloma

Journal for immunotherapy of cancer, 2022-11, Vol.10 (Suppl 2), p.A1265-A1265

2022

Volltextzugriff (PDF)

1 – 25 von 47

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieBlood

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(45)

Publikationsform

Artikel
(47)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(23)
Humans
(21)
Life Sciences & Biomedicine
(20)
Oncology
(15)
Multiple Myeloma
(14)
Cell Line, Tumor
(12)
Antigens
(11)
Hematology
(11)
Immunotherapy
(10)
Lymphocytes
(10)
Multiple Myeloma - Immunology
(10)
T-Lymphocytes, Cytotoxic - Immunology
(10)
Cytotoxicity
(9)
Lymphocytes T
(9)
Peptides
(9)
Multiple Myeloma - Therapy
(8)
Biological And Medical Sciences
(7)
Cd8 Antigen
(7)
Cell Proliferation
(7)
Medical Sciences
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8 + cytotoxic T lymphocytes against multiple myeloma: clinical applications

Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways

Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma

Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8 + cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy

Correction: BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8 + cytotoxic T lymphocytes against multiple myeloma: clinical applications

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

Immunotherapy Strategies in Multiple Myeloma

Phenotypic and Functional Effects of Heat Shock Protein 90 Inhibition on Dendritic Cell

O13-5 Rejuvenated BCMA-specific CD8αβ+ memory T cells to treat multiple myeloma using induced pluripotent stem cell technology

Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors

Development of B-cell maturation antigen (BCMA)-specific CD8 + cytotoxic T lymphocytes using induced pluripotent stem cell technology for multiple myeloma

Correction: BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8.sup.+ cytotoxic T lymphocytes against multiple myeloma: clinical applications

BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8.sup.+ cytotoxic T lymphocytes against multiple myeloma: clinical applications

Enhanced CD138 peptide-specific cytotoxic T lymphocyte activities against breast, colon and pancreatic cancers in combination with pembrolizumab (anti-PD1)

Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8.sup.+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy

Identification of CD19 and CD20 Peptides for Induction of Antigen-Specific CTLs against B-Cell Malignancies

Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial

Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells

OP01-5 Combination immunotherapy targeting XBP1, CD138 and CS1 with cancer vaccine, checkpoint inhibitors, immune modulator, and epigenetic regulator to treat patients with myeloma or solid tumours: Clinical applications

Myeloma-Specific Multiple Peptides Able to Generate Cytotoxic T Lymphocytes: A Potential Therapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders

Heteroclitic CD33 Peptide With Enhanced Anti-Acute Myeloid Leukemic Immunogenicity

A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients

P-083: Rejuvenated BCMA-specific CD8+ Cytotoxic T lymphocytes derived from induced pluripotent stem cells for treatment of Multiple Myeloma

Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma

1220 Development of B cell maturation antigen (BCMA)-specific CD8+ cytotoxic T lymphocytes using induced pluripotent stem cell technology for multiple myeloma

Aktive Filter

Suchergebnisse filtern